Trimetazidine

Description

What is Trimetazidine?

Trimetazidine is a drug for angina pectoris sold under the brand name Vastarel MR. Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity, which results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation. High fatty acid oxidation rates are detrimental during ischemia due to an inhibition of glucose oxidation leading to uncoupling of glycolysis and an increase in proton production, which has the potential to accelerate sodium and calcium overload in the heart, which leads to an exacerbation of ischemic injury and decreased cardiac efficiency during reperfusion.

Basic Information

Product Name:	Trimetazidine
Synonyms:	TRIMETAZIDINE HCL; Trimetazidinum; Trimetazidina
CAS:	5011-34-7
MF:	C14H22N2O3
MW:	266.34
EINECS:	225-690-2
Product Categories:	Pharmaceutical raw materials;APIs;Circulatory system drugs

Chemical Structure

Trimetazidine

Chemical Properties

Boiling point	bp2 200-205°
density	1.092±0.06 g/cm3(Predicted)
pka	9.07±0.10(Predicted)

Trimetazidine Uses

Trimetazidine has the effect of antagonizing epinephrine, norepinephrine and vasopressin. It can directly relax vascular smooth muscle, reduce vascular resistance, increase coronary and peripheral circulation blood flow, and promote myocardial metabolism and myocardial energy production. At the same time, it reduces myocardial oxygen consumption, thereby improving the balance of myocardial oxygen supply and demand. It can increase the tolerance to cardiac glycosides, increase the exercise test tolerance of patients with angina pectoris, significantly reduce the frequency of angina pectoris, and reduce the dosage of nitroglycerin. It is clinically used to treat coronary artery insufficiency, angina pectoris and old myocardial infarction; it can be used in combination with digitalis for patients with severe cardiac insufficiency.

The effect of trimetazidine on the heart may be a direct cytoprotective effect. By preserving the energy metabolism in the ischemic oxygen cells, it prevents the decrease of intracellular ATP levels, while maintaining the stability of the intracellular environment, while ensuring the perfect function of the ion pump. Membrane sodium-potassium pumps function normally, reducing intracellular acidosis and preventing the accumulation of sodium and calcium in myocardial cells, protecting cell contractile function and limiting cell lysis and endometrial damage caused by oxygen free radicals.

Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

MSDS: MSDS available.

COA: COA can be available if you send us inquiry.

Email us at: info@maxmedchem.com for more details.